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Abstract 
Both diabetes and cancer are prevalent diseases whose incidence rates are increasing worldwide, 
especially in countries that are undergoing rapid industrialization changes. Apparently, lifestyle risk 
factors including diet, physical inactivity and obesity play pivotal, yet preventable, roles in the 
etiology of both diseases. Epidemiological studies provide strong evidence that subjects with di-
abetes are at significantly higher risk of developing many forms of cancer and especially solid 
tumors. In addition to pancreatic and breast cancer, the incidence of colorectal cancer and 
prostate cancer is increased in type 2 diabetes. While diabetes (type 2) and cancer share many risk 
factors, the biological links between the two diseases are poorly characterized. In this review, we 
highlight the mechanistic pathways that link diabetes to colorectal and prostate cancer and the use 
of Metformin, a diabetes drug, to prevent and/or treat colorectal and prostate cancer. We review 
the role of AMPK activation in autophagy, oxidative stress, inflammation, apoptosis, and cell cycle 
progression. 
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1. Introduction 
The current worldwide diabetic epidemic is not 
only influencing the morbidity and mortality of the 
present generation, but with no doubt has a 
trans-generational epigenetic inheritance impact with 
increasing prevalence for cancer with Type 2 Diabetes 
Mellitus (T2DM) (1-3). The raised risk of cancer in 
T2DM (4-7), and with a demographic shift in age to-
wards the over 65 years old, translates into consider-
able financial and social burden on finite health care 
budgets. The link between T2DM and raised inci-
dence of colorectal cancer (CRC) and prostate cancer 
(PC), and mortality, has been related to a constellation 
of risk factors pertaining to metabolic syndromes, 
specifically insulin resistance, hyperinsulinemia, and 
hyperglycemia (8-11). A significant point to note here 
is that excessive plasma concentration of insulin and 
glucose correlate with accelerated aging (12). Hence, 
there is an urgent need for targeted therapy for 
comorbid diabetes and cancer. One such medication is 
the old workhorse for T2DM, metformin, which has 
generated considerable attention. Therefore, our re-
view primarily focuses on metformin use in diabetics 
with either colorectal or prostate cancers. The proper-
ties and biological mechanisms of metformin are fur-
ther discussed in relation to diabetes and cancer, fol-
lowed by its applications in in vitro, in vivo and clinical 
studies. 
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2. Biological actions, pharmacokinetics 
and pharmacogenetics of metformin 
The history of metformin, a biguanide deriva-
tive, dates back to the Middle-Ages, and its structural 
analogue galegine was isolated from Galega officinalis 
(goat’s rue, French lilac, Italian fitch); a plant native to 
the Middle East that has been used for treatment of 
diabetes in Europe (13). Accumulating evidence 
shows beneficial survival effects of therapeutic inter-
vention with metformin for cancer patients with 
T2DM (Fig. 1). Metformin, a cationic (hydrophilic 
base) drug, exerts its pleiotropic pharmacological ef-
fects beyond those of metabolic control (14), and in-
cludes favorable anti-inflammatory outcomes (15, 16).  
Information on the pharmacological response to 
metformin requires an understanding of both its 
pharmacokinetics and genetic variation of the differ-
ent transporters for the di-directional movement of 
metformin across plasma membranes (17) (Fig.2). 
Metformin is absorbed from the lumen of the gastro-
intestinal tract (GI) through plasma membrane mon-
oamine transporter (PMAT, or equilibrative nucleo-
side transporter-ENT-4) (18). By its passage through 
the organic cation transporter 1 (OCT1), located in the 
basolateral membrane of human hepatocytes, met-
formin decreases hepatic glucose synthesis (19). In-
deed, this was confirmed by investigations on OCT1 
gene-deficient mice, where the uptake of metformin in 
hepatic and intestinal tissues was lower, compared to 
control animals (19). These studies implied that OCT1 
is pivotal for raising the intracellular concentration of 
metformin; and as a corollary, there was a corre-
sponding derangement in glucose metabolism (19). 
Interestingly, metformin is excreted unmetabolized 
through mutli-drug and toxin extrusion 1 (MATE1) 
and MATE2, located in the apical membrane of kid-
ney proximal tubular cells, into urine (20). Recent 
studies suggest that substantial inter-individual het-
erogeneity in metformin pharmacokinetics exists, and 
this is recognized to be due to genetic variants of dif-
ferent metformin transporter proteins (20-22). Re-
duced expression or altered functionality of trans-
porter proteins will result in less than optimum 
pharmacotherapy or undesirable toxic effects of met-
formin. 
 
 
 
Figure 1. Metformin-mediated amelioration in diabetic and cancerous deranged metabolic profile, improvements in hemostasis and endothelial function, 
with regression of proliferative state. Metformin acts primarily on the liver and reduces glucose output, and secondarily on the peripheral tissues to increase glucose uptake. 
By decreasing gluconeogenesis, it ameliorates hyperglycemia in type 2 diabetes, improves endothelial function, oxidative stress, insulin resistance and fat redistribution. Ac-
cumulating evidence supports the antiproliferative role of metformin in colon and prostate cancer. 
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Figure 2. Metformin transporters: Isoforms and genes that demonstrate a role in metformin pharmacokinetics, pharmacogenetics, and thus have an 
impact on its pharmacological efficacy. Metformin is absorbed from the lumen of the gastrointestinal tract through plasma membrane monoamine transporter (PMAT). It 
requires the organic cation transporters (OCTs), located in the basolateral membrane of human hepatocytes, to be transported into the liver, thus decreasing hepatic glucose 
synthesis. The multidrug and toxin extrusion 1 and 2 (MATE1 and MATE2), located in the apical membrane of kidney proximal tubular cells, facilitate metformin excretion into 
urine. Genetic variation in transporter genes may alter transporter expression and functionality and thus metformin response. 
 
Due to the reduced uptake of glucose from the 
intestinal tract, metformin improves insulin sensitiv-
ity by increasing peripheral glucose absorption and 
utilization by adipose tissue and skeletal muscle. It 
reduces hyperinsulinemia and improves insulin re-
sistance by enhancing the affinity of insulin receptor 
for insulin (23). Moreover, metformin-driven benefits 
negate dyslipidemia by creating a milieu to give rise 
to lower circulating levels of total cholesterol, 
low-density lipoprotein (LDL) and triglycerides (24). 
In addition, administration of metformin to patients 
promotes lower body weight or at least weight neu-
trality (25, 26). Importantly, metformin is a low cost 
drug with a well characterized safety profile in man-
agement of diabetes and cancer. 
3. Pleiotropic effects of metformin 
Multifactorial mechanisms account for metfor-
min’s therapeutic contribution to its anti-oncogenic 
properties. Metformin inhibits complex 1 of mito-
chondrial electron transport chain (27-29), and there-
by attenuates oxidative respiration resulting in 
ATP/AMP ratio imbalance, which in turn activates 
liver kinase B1 (LKB1) and AMPK (29, 30). 
Dephosphorylation by protein phosphatase 2A 
(PP2A) reversibly decreases enzyme efficiency (inac-
tivation) of AMPK. Interestingly, metformin interplay 
with cellular metabolic homeostasis extends to inhi-
bition of AMP deaminase to increase the pool of AMP 
available for activation of AMPK (31). Thus, AMPK 
can choreograph a network of diverse molecular sig-
naling routes depending on the contextual require-
ments for physiological cellular homeostasis and/or 
pathophysiological states (Fig. 3). 
4. Regulation of Energy Homeostasis 
Metformin acts cooperatively with the upstream 
kinase LKB1 to activate AMPK, the master regulator 
of metabolic homeostasis, resulting in the attenuation 
of plasma concentrations of risk factors, namely glu-
cose, insulin, triglycerides and cholesterol (9, 32, 33). 
Metformin, via AMPK, controls the activity and ex-
pression of key regulatory lipid enzymes that have 
been identified in metabolic reprogramming of can-
cers. Phosphorylated AMPK, by upstream metfor-
min-mediated effect, markedly reduces the expression 
(mRNA and protein) of lipogenic transcription factor 
sterol regulatory element-binding protein-1 
(SREBP-1) and hence its targeted genes are also 
downregulated such as fatty acid synthase (FAS) (30, 
34), and 3-hydroxy-3-methyl glutaryl-CoA reductase 
(HMGR, membrane-bound enzyme), which is known 
to reduce HMG-CoA to mevalonate (35). In addition, 
AMPK directly inactivates HMGR by phosphoryla-
tion at serine 872, thus essentially abating cholesterol 
synthesis (36). Also, statins, which are reportedly used 
for anti-cancer therapy, lower cholesterol by inhibit-
ing HMGR (37-39), which is up-regulated in many 
forms of cancers (40). Moreover, the activated form of 
AMPK alters the activity of another type of lipogenic 
enzyme, acetyl-CoA carboxylase (ACC), which exists 
in two isoforms: ACC1 (ACC-α) and ACC2 (ACC-β). 
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Phosphorylation of AAC1 switches on fatty acid 
synthesis through its metabolite malonyl-CoA, while 
ACC2 controls fatty acid oxidation (41). Contextually 
of interest is the silencing by small interfering RNA 
(siRNA) of ACC1 gene that leads to growth arrest and 
caspase-dependent apoptosis of the human lipogenic 
LNCaP prostate cancer cell line (42). Altogether, these 
inhibitory signaling arrays of metabolic activity miti-
gate the burden of cancer-promoting effect of high fat 
diets. 
5. Cell cycle arrest and anti-proliferative 
activity 
Cellular growth-retarding contributions of met-
formin occur downstream from activation of 
LKB1/AMPK pathway, inhibition of mTOR, stabili-
zation of the transcription factor p53 (its degradation 
is suppressed with downregulation of cyclin D1 (43) 
and associated increases in the expression of cy-
clin-dependent kinase inhibitors p27Kip1 and p21Cip1 
(44). The transcription factor p53 contributes to p21 
gene transcription; and up-regulates the expression of 
apoptotic genes (Bax, Caspase-3, 8, 9) (45). These mo-
lecular signaling events channel cells to latency and 
hence drive them to accumulate in the Go/G1 cell cycle 
phase; DNA-damage and fragmentation ensues, 
leading to tumor suppression and further to autoph-
agy and/or apoptosis (46). In addition, metfor-
min-activated AMPK phosphorylates ULK1 at serines 
317 and 777 to ultimately induce mitophagy, au-
tophagy as well as cell death, and subsequently 
apoptosis and reduction of tumor size (47, 48). Fur-
thermore, NF-κB is a transcription factor associated 
with apoptosis, inflammation, oxidative stress and 
neoplastic malignancy, which are all inhibited by 
metformin-stimulated AMPK (48-51). Evidently all of 
this is reflected by the aforementioned investigations 
on cell lines, animal models and beneficial survival 
outcomes of therapeutic intervention studies with 
metformin for cancer-related patients with T2DM. 
 
 
 
Figure 3. Mechanism and Role of AMPK activation. AMP-activated protein kinase (AMPK), a serine/threonine kinase, is an energy sensor whose activity is regulated by 
glucose. AMPK activation, secondary to a change in the AMP/ATP ratio, activation by upstream kinases, such as CAMKK (CaMK kinase) and LKB1, or administration of metformin 
by direct activation of LKB1, slows metabolic reactions that consume ATP and stimulates reactions that produce ATP, thereby restoring the AMP/ATP ratio and the normal 
cellular energy stores. AMPK activation will in turn induce catabolic pathways, such as fatty acid oxidation by inactivating acetyl CoA carboxylase (ACC2), and will inhibit anabolic 
pathways, such as fatty acid synthesis, mediated by ACC1. The mTOR pathway suppresses apoptosis via its effect on the tumor suppressors p53 and p27 and inhibits autophagy 
by suppressing UNC-51-like kinase 1 (ULK1) and ULK2. AMPK activation downregulates the tumorigenic effects of mTOR through the TSC1/TSC2 complex, thus leading to 
increased apoptosis and autophagy-mediated cell death. AMPK activation also inactivates P70S6K and 4E-BP1 subsequently inhibiting protein synthesis. AMPK activation regulates 
the transcription factor FOXO3, which in turn increases antioxidant gene expression. 
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Antiproliferative actions of AMPK, activated by 
metformin, suppress the growth of human umbilical 
vein endothelial cells (HUVEC) (52) as well as human 
and rat aortic smooth muscle cells (16, 53), thus pre-
venting tumor angiogenesis (54). Intuitively, this will 
lead to starving of the tumor of nutrients, thereby 
limiting biosynthetic processes for macromolecules 
and hence cell growth for malignancy. Therefore, such 
multi-actions of AMPK suppress tumors with greater 
efficacy. Also, AMPK directly phosphorylates TSC2 
tumor suppressor (phosphorylated at dual locations: 
threonine 1227 and serine 1345 (55) and raptor (regu-
latory-associated protein of mTOR, phosphorylated at 
serines 722 and 792) (56), a constituent subunit of 
mTORC1 (mammalian target of rapamycin), to sup-
press mTORC1 activity (55, 56). Moreover, metformin 
directly interacts with mTORC1 to inhibit its effects 
downstream, the ribosomal protein S6, S6 kinase 1 
(S6K1) and the translation initiation factor 4E binding 
protein 1 (4E-BP1), and again this induces cell cycle 
arrest and inhibits DNA synthesis (57). 
6. Regulation of oxidative stress 
Metformin arrests hyperinsulinemia-induced 
free radicals (superoxide anion radical, hydroxyl rad-
icals) and reactive oxygen species (ROS, hydrogen 
peroxide), which are integral to oxidative stress (im-
balance between oxidants and antioxidants) and play 
an active mechanistic role in most cancers, and cell 
death is associated with generation of ROS (50, 58-61). 
AMPK in conjunction with the transcription factor 
FOXO3 lessens the fatty acid-induced generation of 
intracellular ROS by up-regulating the expression of 
the antioxidant thioredoxin (62-64), and the reduction 
in NADPH oxidase activity (65). In contrast, reactive 
oxygen species, such as hydrogen peroxide, signifi-
cantly activates the AMPKα sub-unit to inhibit 
mTORC1 signaling and induce apoptosis (66). 
7. Evidence from animal models and 
clinical trials 
Taken together, this implies that metformin may 
lower cancer risk owing to its inherent properties of 
improving an altered metabolic picture, which is re-
flected by a fall in plasma glucose and insulin con-
centrations (32). Evidence from a panel of cancer cell 
lines (43, 67, 68), animal models (43, 68, 69) and epi-
demiological studies (70-73) suggests that metformin 
not only improves the life style and well-being, but 
lowers the rates of mortality in CRC (74) and PC (75). 
Multi-ethnic epidemiological studies have revealed 
disparity between ethnic groups of patients with PC 
risk due to diabetes and/or different medication 
(metformin) (6, 73, 75). However, in one of the latter 
meta-analysis studies on PC, the authors added a ca-
veat that additional long-term investigations on the 
use of metformin for PC must be forthcoming for 
concrete confirmation of the available data (75). Ap-
propriately, triggered by these promising an-
ti-tumorigenic benefits of metformin, epidemiologists 
have initiated clinical trials centered on a variety of 
tumors, including colorectal (5 ongoing clinical trials) 
and prostate (3 ongoing clinical trials) cancers with 
diabetes, and these can be located at 
http://www.clinicaltrials.gov/ website. 
Continuing from above, recent evidence has 
commenced a debate on whether AMPK is a sup-
pressor of cancer or an oncogenic member of signaling 
cascade (76, 77). This is perhaps an issue of the extent 
of AMPK activation, where at low activity it may not 
be a potent anti-cancer agent, but sustained high ac-
tivation may be critical for inhibition on growth and 
survival of tumors. In the same context, it is not clear 
from the literature if any dose response curves for 
metformin as a chemotherapeutic agent have been 
performed on AMPK activity. Consideration must be 
given to the subject of genetic polymorphism of or-
ganic cation transporters (OCT1 and OCT2), which 
may affect the population-based individual variability 
and hence clinical efficacy of metformin (78). There-
fore, this necessitates further studies to ensure and to 
consolidate that the thesis on metformin-activated 
AMPK is water-tight as an inhibitor of proliferative 
growth in cancers. 
To conclude, recent advances in pinpointing the 
molecular control points that orchestrate the myriad 
of transduction pathways is pivotal to personalized 
therapy for cancer and other treatments, and the 
metformin research has rightly focused on AMPK, the 
master metabolic sensor. On a cautionary note, tu-
mors are heterogeneous by character, and as Mother 
Nature has its own surprises, therefore it may be 
prudent to target more than one molecule as this ap-
proach may be more efficacious. Overall though, the 
preceding statements confirm that metformin is as a 
mono-therapeutic agent with multi-fold targets (Table 
1 and 2). 
8. Perspectives 
Although an arsenal of therapeutic drugs is 
available for the management of different categories 
of cancer with type 2 diabetes mellitus, metformin 
remains the most widely used medication for T2DM. 
Recently, AMPK has received considerable attention 
regarding its central role as a metabolic homeostasis 
sustaining rheo-transducer as well as an inter-link 
between signaling routes between diabetes and can-
cer. Further preclinical and clinical investigations are 
ongoing to evaluate the therapeutic benefits of met-
formin on AMPK activation as an anti-diabetic, an-
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ti-proliferative, hypoinsulinemic, apoptotic and hence 
anti-carcinogenic agent. Indeed, results with metfor-
min demonstrate that AMPK is an ideal target for 
activation in both CRC and PC, and moreover met-
formin has other beneficial pleotropic targets in addi-
tion to metabolic control. In this context, and consid-
ering the afore-mentioned paragraphs, its effects on 
aberrant homeostasis in T2DM, CRC and PC are truly 
remarkable. Hence, it potentially holds substantial 
promise as a positive dual modifier of deranged 
metabolic homeostasis and as an anti-neoplastic 
agent. 
 
Table 1. From Bench to Bedside: the use of metformin from cultured cells to clinical trials. 
Cell lines Animal Studies Clinical Trials 
a). Xiang X, Saha AK, Wen R, Ruder-
man NB, Luo Z, 2004. AMP-activated 
protein kinase activators can inhibit the 
growth of prostate cancer cells by 
multiple mechanisms. Biochem Bio-
phys Res Commun. 321:161-167. 
a). Buzzai M, Jones RG, Amaravadi RK, Lum JJ, 
DeBerardinis RJ, Zhao F, Viollet B & Thompson CB 
2007 Systemic treatment with the antidiabetic drug 
metformin selectively impairs p53-deficient tumor 
cell growth. Cancer Research 67 6745–6752. 
i). Search identifier at clinicaltrial.gov/ Metfor-
min/colorectal cancer/diabetes 
b). Ben Sahra I, Laurent K, Loubat A, 
Giorgetti-Peraldi S, Colosetti P, Au-
berger P, Tanti JF, Le Marchand-Brustel 
Y, Bost F, (2008). The antidiabetic drug 
metformin exerts an antitumoral effect 
in vitro and in vivo through a decrease 
of cyclin D1 level. Oncogene 
27(25):3576–3586. Proliferation of 
DU145, PC-3, LNCaP cancer cells; 
xenografts of LNCaP, reduction of 
cyclin D1 protein level 
b). Ben Sahra I, Laurent K, Loubat A, Giorget-
ti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le 
Marchand-Brustel Y, Bost F, (2008). The antidiabetic 
drug metformin exerts an antitumoral effect in vitro 
and in vivo through a decrease of cyclin D1 level. 
Oncogene 27(25):3576–3586. 
Status Study Clinical trials. 
gov identifier 
c). Ben Sahra I, Laurent K, Giuliano S, 
et al. Targeting cancer cell metabolism: 
the combination of metformin and 
2-deoxyglucose induces p53-dependent 
apoptosis in prostate cancer cells. 
Cancer Research 2010;70:2465–75. 
c). Huang X, Wullschleger S, Shpiro N, McGuire VA, 
Sakamoto K, Woods YL, McBurnie W, Fleming S, 
Alessi DR. Important role of the LKB1-AMPK path-
way in suppressing tumorigenesis in PTEN-deficient 
mice. Biochem J. 2008 Jun 1;412(2):211-21. 
Recruiting Exercise and Metformin 
in Colorectal and breast 
cancer Survivors 
NCT01340300 
d). Zakikhani, M., Dowling, R.J., 
Sonenberg, N., Pollak, M.N., (2008). 
The effects of adiponectin and metfor-
min on prostate and colon neoplasia 
involve activation of AMP-activated 
protein kinase. Cancer Prev Res (Phila 
Pa) 1: 369–375. Metformin-mediated 
AMPK activation decrease cell growth 
and protein synthesis 
d). Tomimoto A, Endo H, Sugiyama M, Fujisawa T, 
Hosono K, Takahashi H, Nakajima N, Nagashima Y, 
Wada K, Nakagama H et al. 2008 Metformin sup-
presses intestinal polyp growth in ApcMin/C mice. 
Cancer Science 99 2136–2141. 
Recruiting Impact of pretreatment 
with Metformin on colo-
rectal cancer Stem cells 
(CCSC) and related 
Pharmacodynamics 
markers 
NCT01440127 
  e). Algire C, Amrein L, Zakikhani M, Panasci L, 
Pollak M. Metformin blocks the stimulative effect of a 
high-energy diet on colon carcinoma growth in vivo 
and is associated with reduced expression of fatty 
acid synthase. Endocr Relat Cancer. 2010 Jun 
1;17(2):351-60. 
Recruiting An open-labeled pilot 
study of biomarker re-
sponse following 
short-term exposure to 
metformin 
NCT01816659 
  f). Hosono K, Endo H, Takahashi H, Sugiyama M, 
Uchiyama T, Suzuki K, Nozaki Y, Yoneda K, Fujita K, 
Yoneda M, Inamori M, Tomatsu A, Chihara T, 
Shimpo K, Nakagama H, Nakajima A, 2010. Metfor-
min suppresses azoxymethane-induced colorectal 
aberrant crypt foci by activating AMP-activated 
protein kinase. Mol Carcinog. 49:662-671. 
Not yet 
recruiting 
The chemopreventive 
effect of Metformin in 
patients with familial 
adenomatous polyposis: 
double blinded random-
ized controlled study 
 
NCT01725490 
    ii). Search identifier at clinicaltrial.gov/ Metfor-
min/prostate cancer/diabetes 
    Status Study Clinical trials. 
gov identifier 
    Recruiting Metformin-Docetaxel 
Association Colorectal 
and breast cancer Survi-
vors 
NCT01796028 
    Active not 
recruiting 
Metformin in castration - 
resistant Metformin on 
colorectal cancer Stem 
cells (CCSC) and related 
Pharmacodynamics 
markers 
NCT01215032 
    Recruiting Castration compared to 
castration Plus metformin 
as first line treatment For 
patients with advanced 
prostate cancer 
 
NCT01620593 
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Table 2: Epidemiological Investigations. 
a) Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR & Morris AD 2005 Metformin and reduced risk of cancer in diabetic patients. BMJ 330 1304–1305. 
b) Larsson SC, Orsini N, Wolk A, 2005. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97:1679-1687. 
c) Bowker SL, Majumdar SR, Veugelers P & Johnson JA 2006 Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or 
insulin. Diabetes Care 29 254–258. 
d) Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:2056-62. 
e) Kasper JS, Liu Y, Giovannucci E. Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer. 2009 Mar 
15;124(6):1398-403. 
f) Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people 
with type 2 diabetes. Diabetes Care 2009;32:1620-5. 
g) Wright, J.L., Stanford, J.L., 2009. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes 
Control 20: 1617-1622. 
h) Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S. Metformin and cancer risk in diabetic patients: a systematic review and 
meta-analysis. Cancer Prev Res (Phila). 2010 Nov;3(11):1451-61. 
i). Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T, Suzuki K, Iida H, Sakamoto Y, Yoneda K, Koide T, Tokoro C, Abe Y, Inamori M, Nak-
agama H, Nakajima A. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila). 2010 Sep;3(9):1077-83. 
j) Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. 
Diabetes Care. 2010 Feb;33(2):322-6. 
k). Azoulay L, Dell'Aniello S, Gagnon B, Pollak M, Suissa S. Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol 
Biomarkers Prev. 2011 Feb;20(2): 337-44. - this study indicates that metformin does not reduce the risk of prostate cancer in patients with type 2 diabetes. 
l). Lee MS, Hsu CC, Wahlqvist ML, et al. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a 
representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011;11:20 
m) Monami M, Colombi C, Balzi D, et al. Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2011;34:129-131 
n) Zhang ZJ, Zheng ZJ, Kan H, Song Y, Cui W, Zhao G, Kip KE. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a 
meta-analysis. Diabetes Care. 2011 Oct;34(10):2323-8. 
o) Deng L, Gui Z, Zhao L, Wang J, Shen L, 2012. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. Dig 
Dis Sci 57: 1576-1585. 
p) Garrett CR, Hassabo HM, Bhadkamkar NA, Wen S, Baladandayuthapani V, Kee BK, Eng C, Hassan MM. Survival advantage observed with the use of met-
formin in patients with type II diabetes and colorectal cancer. Br J Cancer. 2012 Apr 10;106(8):1374-8. 
q) Higurashi T, Takahashi H, Endo H, Hosono K, Yamada E, Ohkubo H, Sakai E, Uchiyama T, Hata Y, Fujisawa N, Uchiyama S, Ezuka A, Nagase H, Kessoku T, 
Matsuhashi N, Yamanaka S, Inayama Y, Morita S, Nakajima A. Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial. 
BMC Cancer. 2012 Mar 26; 12: 118. 
r) Lee JH, Jeon SM, Hong SP, Cheon JH, Kim TI, Kim WH. Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients 
with previous colorectal cancer. Dig Liver Dis. 2012 Dec;44(12):1042-7. 
s) Lee, J.H., Kim II, T., Jeon, S.M., Hong, S.P., Cheon, J.H., Kim, W.H., 2012. The effects of metformin on the survival of colorectal cancer patients with diabetes 
mellitus. Int J Cancer 131: 752-759. 
t) Noto H, Goto A, Tsujimoto T, Noda M (2012). Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS ONE 7: 
e33411. 
u) Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, Straus SM, Herings RM, Stricker BH, 2012. Lower risk of cancer in 
patients on metformin in comparison with those on sulfonylurea derivatives: Results from a large population-based follow-up study. Diabetes Care 35: 119–124.  
v) Soranna D, Scotti L, Zambon A, Bosetti C, Grassi G, Catapano A, La Vecchia C, Mancia G, Corrao G. Cancer risk associated with use of metformin and sul-
fonylurea in type 2 diabetes: a meta-analysis. Oncologist. 2012;17(6):813-22. 
w). Chung HH, Moon JS, Yoon JS, Lee HW, Won KC. The Relationship between Metformin and Cancer in Patients with Type 2 Diabetes. Diabetes Metab J. 2013 
Apr;37(2): 125-31. 
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